Gelonghui, September 25 | China Biopharmaceutical (01177.HK) announced that the “Lisimin Transdermal Patch” (trade name: Debaitai) developed by the Group has obtained marketing approval from China's State Drug Administration to treat mild and moderate symptoms of Alzheimer's disease. This is the first domestically produced Leasming transdermal patch approved for marketing.
According to the disclosure, listigmine is a cholinesterase inhibitor used to treat Alzheimer's disease. Acetylcholine is an important neurotransmitter that transmits information between neurons and plays a key role in brain regions associated with memory and learning. By inhibiting the activity of acetylcholinesterase (AChE) and butyylcholinesterase (BuChE), listimine reduces the degradation of acetylcholine, thereby increasing the level of acetylcholine in the central nervous system and improving patients' cognitive function.
Lisimin transdermal patches can achieve continuous and stable drug release over a long period of time, maintain stable patient blood concentration, and reduce side effects and drug efficacy fluctuations caused by fluctuations in drug concentration. Furthermore, transdermal administration enhances patient compliance, simplifies drug administration, and is suitable for sleeping patients who are unresponsive or unable to swallow oral medications, providing patients with a more comfortable treatment option.
